Pertussis bacteria nucleic acid detection kit &☆(PCR-fluorescent probe metho÷<¶d)
Clinical background
Pertussis is a bacterial res£±↕piratory infection caused by Bordetella per♥♥'≠tussis infection. People of all ≈§φ≠ages are susceptible to it,δ> but infants and chi®≥&≠ldren are more seriously ill than adults™≠ after infection. According toε♠ the World Health Organσ✘∑ization (WHO) statistical reporπ'∏"t, in 2013, whooping cough caused the death∞♦ of nearly 63,000 infants and children unde$€r 5 years of age. In recent years, t★↕he infection of whooping coug★φh in China has been on the rise, and &®even broke out in some areas. Accordβ®₽ ing to the clinical big d¶<ata analysis carried out by our company, the higα∑≥§h incidence season of whooping cough is ©±generally from March to SeptembeΩ÷§∑r, and the incidence rate can reach★ ♥ more than 30%.
Whooping cough reappears globally, and smaσll babies are critical, and accurate diagnosis✔™↔ has been put on higher dem ♥βands in the new era!
Clinical manifestations
Pertussis is clinically divided✘σ☆↔ into three stages: the ✔↓incubation period, the spasm↔¶₹ period, and the recovery period; the
epidemic season has p&≠aroxysmal spasm cough or vomiting after c€₽ough, and the severe cases have subconjunctival §$→≈hemorrhage or tongue ulcer.
Neonate or infant There are unexplained episodes ™ of bruising or suffocation, w↓hich are mostly typica♣ l spasms.
Persistent cough, accompan≤✘÷ied by chicken cries, andα™ increased lymphocytes in the periphera∑₩♣l blood.
Complications of B. ¶Ω↔pertussis infection
Respiratory diseases:↑★ bronchial pneumonia; bronchiectasis; pneu₽©δ"mothorax; diaphragmatic he≤ rnia, etc.
Central diseases: Pertussis encephalopathy
Others: otitis media; bleeding; hernia etc.....
Features
Based on real-time fluorescent PCR technologλγδy, the first CFDA registered product in "£βChina.
The reaction system of thisλ≠β kit contains a dU-UNG enzyme anti-pollution★♥ system to avoid false positive results; ★£the system contains internal s×↓tandards to avoid false negative results.
Using highly conserved regions of the B. pertussi™πΩs genome as the target area, specific✘¶& primers and fluorescent probeγ><s are designed to perform PCR amplification to enβε≥sure the accuracy of♥γ the product.
Carry out big data clinical verification±₩≥ covering national represen₹☆δtative clinical units, ♠★$☆with outstanding produc↑£₩✔t performance.
Product performance
|
Pertussis bacteria nucleic acid detec✘ ♠←tion kit (PCR-fluorescent pro↔•<be method)
|
|
Sensitivity
|
1.0x104copies / mL
|
|
Linear range
|
1.0x104copies / mL ~ 1.0x 109copies / mL
|
|
Accuracy
|
The detection result coincidence rate is 100%©©
|
|
Precision
|
Coefficient of variatio↔©"n within and between batches CV≤5%
|
|
Specificity
|
100% specificity, no cross reaction with Stre×€ptococcus pneumoniae, Mycobacteri'δ✔¥um tuberculosis, Mycoplasma pneu¶<moniae, Epstein-Barr '≠β♠virus, adenovirus, rφ≤espiratory syncytial virus,✘✘ etc.
|
|
Anti-interference
|
Mucin, pus, erythromycin, chloram δ&★phenicol did not interfere with the test re§λ<♥sults
|
Application field
Applicable people: dry cough or paroxysmal spasm, accompanied by ≈ chicken-like roar or vomiting after cough witho∏ ut other causes for laboratory diagnos"←π is of B. pertussis
Applicable departments: pediatrics, infections, otolaryngology, etc.
Product information
Test specimen: pharyngeal swab
Technical principle: PCR-fluorescent probe method
Packaging specifications: 24 tests/ kit, 48 tests/ kit♥, 96 tests/ kit
Applicable instruments: two-color fluorescence channel PCR instrument, ™•including ABI 7500, ABI 7300 , Roche480, Roche9 ₩↓6, etc.
